F2G

AcronymDefinition
F2GFree to Go (mobile phone package)
References in periodicals archive ?
"It is understood that the company transferred all of its assets and employees on or around April 1, 2014, to Floors to Go and the business is being traded by F2G Retail Sales.
Our proposed reversible 4-bit squarer design has 4 F2G gates for generating the necessary fan-out inputs in the first stage.
But a new firm F2G Retail Sales took on the Behar name and supplied her with an alternative from stock.
John Rex, Chief Medical Officer at F2G will be presenting at this year's conference on "Anti-Infective Research: Funding, Filing and Finance", where he will provide updates on funding initiatives, recent changes in the regulatory landscape, and payer models: evolving global discussions.
Manchester, UK-based F2G Ltd has named Ralf Schmid as its new chief financial officer, it is reported today.
Manchester University spin-out firm, F2G has welcomed the support of Advent Life Sciences and Novartis Bioventures.
Achaogen, Amplyx Pharmaceuticals, Centauri Therapeutics, ContraFect, DeNovaMed, Emergent BioSolutions, Evotec, F2G Ltd, HHS/ASPR/BARDA, Janssen Research & Development, Laboratoire Biodim, Macrolide Pharmaceuticals, MedImmune, Merck, Microbiotix, Micron Research, Morton Findlay Associates, Motif BioSciences, N8 Medical, NeoSome Life Sciences, Novo AS, Pfizer, Rutgers University, Soligenix, Teleflex, UNT Health Science Center, UNTHSC, PreClinical Services, Visterra, Weber Shandwick.
Manchester, United Kingdom, December 03, 2015 --(PR.com)-- F2G Ltd, a UK based antifungal drug discovery and development company, today announced that its novel systemic antifungal product F901318 has been accepted to participate in the European Medicines Agency's (EMA) Adaptive Pathways pilot programme.
Manchester, United Kingdom, September 04, 2014 --(PR.com)-- F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/oral systemic antifungal (F901318) with the commencement of a Phase I clinical study.
Manchester, United Kingdom, June 28, 2013 --(PR.com)-- F2G Ltd, a privately-held antifungal drug discovery and development company and The University of Manchester, today announced the commencement of a 6.1 million euro EU-funded project to discover and develop novel antifungal drugs to treat serious, life-threatening fungal infections.
Manchester, United Kingdom, March 20, 2013 --(PR.com)-- F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of Ian Nicholson to the position of CEO and to the Board of Directors.
Manchester, United Kingdom, September 13, 2010 --(PR.com)-- F2G Limited, the UK based antifungal drug discovery and development company, today announced the appointment of Dr Michael R.